{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Global+Alliance+for+TB+Drug+Development",
    "query": {
      "sponsor": "Global Alliance for TB Drug Development"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Global+Alliance+for+TB+Drug+Development&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T12:44:16.624Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03199339",
      "title": "A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "TBA-7371",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 74,
      "start_date": "2017-08-29",
      "completion_date": "2018-07-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-17",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199339"
    },
    {
      "nct_id": "NCT01768273",
      "title": "Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "PA-824",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 14,
      "start_date": "2009-12",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01768273"
    },
    {
      "nct_id": "NCT04493671",
      "title": "Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Disease",
        "Tuberculosis, Pulmonary",
        "Tuberculosis",
        "Multi Drug Resistant Tuberculosis",
        "Drug Sensitive Tuberculosis",
        "Drug-resistant Tuberculosis",
        "Mycobacterium Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "TBAJ-876 suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo suspension",
          "type": "DRUG"
        },
        {
          "name": "TBAJ-876 100 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "TBAJ-876 25 mg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 137,
      "start_date": "2020-06-08",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2025-06-04",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04493671"
    },
    {
      "nct_id": "NCT03199313",
      "title": "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "Sutezolid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-09-26",
      "completion_date": "2017-12-16",
      "has_results": false,
      "last_update_posted_date": "2018-02-08",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199313"
    },
    {
      "nct_id": "NCT01828827",
      "title": "Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "PA-824 1000 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 16,
      "start_date": "2007-03",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2016-01-14",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01828827"
    },
    {
      "nct_id": "NCT02288481",
      "title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "TBA-354",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2015-01",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288481"
    },
    {
      "nct_id": "NCT04309656",
      "title": "Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multi-drug Resistant Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Pretomanid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 48,
      "start_date": "2020-01-14",
      "completion_date": "2020-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-07-24",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04309656"
    },
    {
      "nct_id": "NCT02216331",
      "title": "PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "TMC207",
          "type": "DRUG"
        },
        {
          "name": "rifapentine",
          "type": "DRUG"
        },
        {
          "name": "rifampicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "19 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-03",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2019-09-06",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02216331"
    },
    {
      "nct_id": "NCT00144417",
      "title": "TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)",
          "type": "DRUG"
        },
        {
          "name": "isoniazid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 433,
      "start_date": "2006-02",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2011-08-03",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 20,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00144417"
    },
    {
      "nct_id": "NCT04865536",
      "title": "Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis",
        "Tuberculosis, Pulmonary"
      ],
      "interventions": [
        {
          "name": "TBI-223 1800 mg",
          "type": "DRUG"
        },
        {
          "name": "TBI-223 2400mg",
          "type": "DRUG"
        },
        {
          "name": "TBI-223 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Global Alliance for TB Drug Development",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "19 Years to 50 Years"
      },
      "enrollment_count": 28,
      "start_date": "2021-02-03",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-05",
      "last_synced_at": "2026-10-05T12:44:16.624Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04865536"
    }
  ]
}